详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Prognosis value of RBBP8 expression in plasma cell myeloma

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing 100191, China [2]Gannan Medical University, Ganzhou 341000, China [3]Department of Pathology, Beijing Tiantan Hospital Affiliated with Capital Medical University, No. 6 Tiantan Xili, Beijing 100050, China [4]Department of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China [5]Melbourne School of Population and Global Health, The University of Melbourne, Victoria 3010, Australia

出处：

DOI：

ISSN：

摘要：

Plasma cell myeloma (PCM) secretes monoclonal immunoglobulin (Ig) by clonal plasma cells of abnormal proliferation in the bone marrow. As PCM is incurable, it is necessary to find new biomarkers to predict the prognosis and recurrence of PCM. The relationship between cancer and RBBP8 has not been fully studied. The role of RBBP8 in tumorigenesis remains inconsistent. We described the expression of RBBP8 in the gene expression profile of 1930 PCM samples (1878 PCM patients) from seven independent data sets. We analyzed the relationship between RBBP8 and survival prognosis, recurrence, and treatment response in patients with PCM, and the biological significance of RBBP8 in PCM. The gene expression level of RBBP8 was significantly related to the International staging system (ISS) grade of PCM (P = 0.0012). RBBP8 expression in different molecular subtypes was different (P < 2.2e-16). High RBBP8 expression is associated with poor survival in PCM (P < 0.0001). High expression of RBBP8 indicates that PCM patients are more likely to relapse (P = 0.0078). The biological significance of RBBP8 in PCM is related to the cell cycle (P < 0.05). High RBBP8 expression predicts poorer survival and more likely relapse in PCM. RBBP8 plays an important role in the cell cycle of PCM. RBBP8 can be considered an independent prognostic factor for PCM. RBBP8 can be used as a potential biomarker for assessing the prognosis of PCM patients. © 2019, The Author(s).

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 2 区医学

小类 | 3 区生物工程与应用微生物 3 区遗传学 3 区医学：研究与实验 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 2 区生物工程与应用微生物 3 区遗传学 3 区医学：研究与实验 4 区肿瘤学

JCR分区：

出版当年[2017]版：

Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 GENETICS & HEREDITY Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

最新[2023]版：

Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 GENETICS & HEREDITY Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

影响因子： 4.8 最新[2023版] 4.9 最新五年平均 4.044 出版当年[2017版] 3.008 出版当年五年平均 3.652 出版前一年[2016版] 4.681 出版后一年[2018版]

第一作者：

第一作者机构： [1]Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing 100191, China

通讯作者：

通讯机构： [1]Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing 100191, China [3]Department of Pathology, Beijing Tiantan Hospital Affiliated with Capital Medical University, No. 6 Tiantan Xili, Beijing 100050, China [4]Department of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China

推荐引用方式(GB/T 7714)：

APA：

MLA：